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tinuous therapy. The risk of discontinuation/switching was not
statistically different between the two groups. Patients who used
a CNS medication before initiation of therapy, did not visit their
physician ofﬁce frequently or were not hospitalized after initia-
tion of ChEI therapy were more likely to discontinue/switch their
initial ChEI. CONCLUSION: Levels of persistency among the
elderly patients with AD is similar between rivastigmine and
donepezil in a real-world setting. Further research is needed to
determine ways of improving persistency and to estimate the
long-term economic impact of persistency with ChEIs on AD
treatment costs.
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OBJECTIVES: Recent research has shown that antidepressants
may improve non-cognitive symptoms in patients with
Alzheimer’s disease (AD). The economic beneﬁts of antidepres-
sant use in this population are unknown. This study investigated
whether antidepressants use by AD patients could delay the
admission to long-term care (LTC) treatment and reduce total
costs. METHODS: Patients diagnosed with AD from 1995–2001
were retrieved from a 20% sample of the California Medicaid
(Medi-Cal) claims database. The index date for the antidepres-
sant group was deﬁned as the dispensing date of ﬁrst antide-
pressant medication, and for the control group, it was deﬁned 
as the date of initial AD diagnosis. Generalized linear models
(GLM) with log link function and gamma distribution were
applied to compare the ﬁrst year total post-index medical (non-
pharmacy) costs and the total health care costs between the
groups, controlling for demographics, comorbidities, and prior
utilization. Cox proportional hazard regression was used to
model the time to ﬁrst LTC admission since index date, adjust-
ing for the same set of covariates. RESULTS: In total, 3515 AD
patients were identiﬁed, with 1645 in the antidepressant group
and 1870 in the control. AD patients with antidepressants were
younger (77 vs. 80 years, p < 0.0001), had higher proportion of
Caucasians (57% vs. 53%, p < 0.0001), and had a similar
comorbidity proﬁle as the control group. Adjusted for potential
confounders, the GLM estimates showed that using antidepres-
sants was related to 40% and 36% lower post-index total
medical costs and total health care costs (p < 0.0001 for both),
respectively. In the Cox regression, antidepressant group had
34% lower risk of admission to LTC than the control group 
(P < 0.0001). CONCLUSIONS: In this study, antidepressant use
in AD patients associated a signiﬁcant reduction in total costs
and appeared to postpone long-term care admission.
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OBJECTIVES: Although acetylcholinesterase inhibitors (AChEI)
are the only class of drugs indicated for Alzheimer’s disease (AD),
drugs treating non-cognitive symptoms and drugs possibly ben-
eﬁcial to cognitive functions (e.g. estrogen, selegiline) are also
prescribed for AD patients in practice. This study investigated 1)
Characteristics of physicians giving the initial AD diagnosis; 2)
prescription choice and patterns for AD in a Medicaid popula-
tion. METHODS: AD Patients with a minimum of 12 months
continuous eligibility after initial diagnosis of AD were identi-
ﬁed from a 20% Medi-Cal claims database of 1995–2002.
During the ﬁrst year follow-up, the prescription claims of the 
following drug classes were analyzed: AChEI, antidepressants,
antianxiety agents, antipsychotics, estrogen and antiparkinson-
ian MAO inhibitor (e.g. selegiline). Regression models were
applied to study the prescription pattern. RESULTS: A total of
4386 AD patients were initially diagnosed by 2205 unique physi-
cians. Among 1055 AD patients diagnosed by physicians with
specialty information, 35.5% were diagnosed by primary care
physicians (PCPs), 22.6% by internists, 19.4% by neurologists,
4.3% by psychiatrist, and the rest by other specialists. During
the ﬁrst year of follow up, 42.5% patients did not receive any
AD-related medications. Controlling for demographics, diagno-
sis year and comorbidities, patients diagnosed by PCPs were least
likely to get any prescription compared to neurologists (OR =
1.64, p = 0.01), and psychiatrists (OR = 2.22, p = 0.0065).
Antipsychotics were the most frequently prescribed drugs
(34.0% patients), followed by antidepressants (27.2%), and
antianxiety agents (16.1%). Only 22.3% of patients diagnosed
after 1997, when AChEI became available, received drugs in this
class. 27.5% patients received more than one class of drugs.
From 1995–2002, drug treatment was increasing for all classes
except estrogen and selegiline. CONCLUSIONS: Although use
of medications increased over years, patients with AD seemed to
be under-treated, especially those diagnosed by PCPs. Contrary
to guideline recommendations, most treated patients only
received drugs for non-cognitive symptoms.
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The feasibility and accuracy of obtaining patient reported out-
comes electronically, particularly from elderly subjects, has been
questioned. OBJECTIVE: To pilot the use of a telephone-based
Interactive Voice Response Data Entry System (IVRS) by elderly
caregivers of patients with Alzheimer’s Disease. METHODS:
Caregivers were trained by nurses to record patient and caregiver
health care utilization data into a 30-day diary and to enter these
data using IVRS. The system was accessed via a toll-free tele-
phone number using a unique subject identiﬁer. Caregivers had
15 minutes to read detailed training notes in the waiting room.
Feasibility and accuracy parameters assessed were time to train,
time to enter the data and accuracy of hypothetical diary data
entry. RESULTS: Time to train the caregiver (60% women, 52
to 80+ years old) on both the use of the diary and IVRS data
entry ranged from 36 to 48 minutes. Thirty days of hypotheti-
cal diary data provided to the patient for the exercise were
entered via IVRS in 8 to 12 minutes per subject. No signiﬁcant
difﬁculties were observed with any caregiver and only one data
point by one caregiver was incorrectly entered. IVRS features
such as question repeat, invalid answer prompt, and automatic
re-entry to last question answered if entry was interrupted all
worked well. Caregivers expressed their willingness to use the
diary daily and to enter data every 30 days over the planned 18-
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month study. All study nurses expressed their preference for this
design versus a traditional nurse interview, paper-based design,
primarily due to decreased site burden in relation to data col-
lection. CONCLUSIONS: The use of a prospective diary and
IVRS data entry by the elderly is feasible and offers the possi-
bility to collect detailed prospective health economic data with
a minimum of burden to site study staff.
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OBJECTIVES: To estimate health care costs of patients with
partial refractory epilepsy (PRE) in the Mexican Institute of
Social Security (IMSS). METHODS: PRE requires long-term
health costly care with two or more anti-epileptic drugs, pres-
ence of intolerance and side effects. Case series with PRE diag-
nosis in four hospitals in Mexico City which inclusion criteria
were: aged 12 and older, using two or more anti-epileptic drugs
and information available of at least one-year follow-up period.
Cost evaluation perspective was that from services provider, 
time horizon was one year and three costing techniques were
combined: micro-costing, average cost and cost per diem, using
a bottom-up aproach. Costs are expressed in 2004 USD.
RESULTS: From medical records (813), 133 were correctly diag-
nosed as PRE and 72 cases met inclusion criteria. Demographic
characteristics: 58% were females, 64% were between 12–35
years old, 47% students, 58% single and 73% had intermediate
or preparatory education. Fifty one percent had simple partial
seizures and 94% more than one crisis per month. Mean annual
visits per patient to general practitioner was 5.2 and to neurol-
ogists 6.8; laboratory tests 6.0 and electroencephalographic
studies 0.8. Total annual cost of health care was $2646 per
patient and 24% was derived from hospitalisation. Total cost
was distributed in: 39% visits, 24% drugs, 21% bed days and
16% diagnostic tests. First line drugs were Carbamazepine 
and Valproic acid (more than 68%), while second line ones 
Clonazepam (36%), Lamotrigine (33%) and Topiramate (21%).
CONCLUSIONS: Most of patients were young, in productive
age and had more than one seizure per month; this is a matter
of concern because a difﬁcult seizure control affects negatively
patient and family social life, including employment. Effective-
ness, safety and cost of available drugs are crucial issues in
control and quality of life of PRE patients.
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OBJECTIVE: To evaluate the psychometric properties of 
disease-speciﬁc quality of life (QOL) instruments in epilepsy.
METHODS: A comprehensive search for epilepsy-speciﬁc QOL
instruments identiﬁed 13 metrics using MEDLINE, Pubmed,
International Pharmacy Abstracts, Google and reference lists.
QOL instruments were included in the study for evaluation if
there was at least one publication using the instrument includ-
ing psychometric data, in addition to instrument availability.
Instruments were evaluated based on criteria developed by
McHorney and Tarlov (1995) and Davis and Pathak (2001). The
seven domains considered in the evaluation were: item informa-
tion, practicality, breadth and depth of health measured, relia-
bility, validity, and responsiveness. RESULTS: Of the 13 QOL
instruments identiﬁed, adequate data was available to evaluate
ﬁve based on study criteria. The ﬁve epilepsy-speciﬁc QOL
metrics were: Quality of Life in Newly Diagnosed Epilepsy
(NEWQOL), Epilepsy Surgery Inventory (ESI-55), and the
Quality of Life in Epilepsy Inventory (QOLIE) series (-89, -31,
and -10). None of these ﬁve QOL metrics satisﬁed all the study
criteria. The QOLIE-31 reported adequate or better performance
in six of the seven domains assessed (omitting instrument
breadth). The QOLIE-10 reported adequate or better perfor-
mance in ﬁve of the seven domains assessed (omitting instrument
breadth and internal consistency). The QOLIE-10 and -31 offer
practical advantages over the longer QOLIE-89 metric with
QOLIE-31 showing superior psychometric properties based on
study results. CONCLUSIONS: Epilepsy is a chronic, socially
stigmatizing condition with potentially signiﬁcant affects on
patient QOL. A variety of instruments have been published in
the literature with QOLIE-89 most commonly used. Of the data
available for QOLIE series, the length of the QOLIE-89 limits
its use in clinical decision making, while the brevity of QOLIE-
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OBJECTIVES: A composite outcome measure in migraine treat-
ment assessment is useful to clinical decision makers and payers
as it provides a more accurate reﬂection of effectiveness and
allows for more complete modeling of economic value. This
composite measure must consider both short- and long-term
treatment effects, as well as placebo effects. The objective of this
study was to compare the total triptan cost to treat 100 migraine-
patient attacks and the cost per successfully treated patient
(CPSTP) for six marketed triptans using a composite measure 
of effectiveness, the ‘successfully treated’ migraine (deﬁned as
requiring only one triptan dose to treat one migraine attack
during a 24-hour period). METHODS: This analysis was con-
ducted from the perspective of the payer. Clinical data were
abstracted from a rigorous, published meta-analysis. Two-hour
response and pain-free response were used in conjunction with
the recurrence rate reported in the meta-analysis to calculate the
number of doses used by treatment successes and failures. The
average wholesale price per dose was then used to calculate total
triptan cost. RESULTS: Of the nine oral triptan doses compared,
eletriptan 40mg was associated with both the lowest total triptan
cost for treating 100 migraine attacks ($1560) and with the
lowest CPSTP ($56.39). CONCLUSIONS: The relative CPSTP
for migraine therapies is dependent on the deﬁnition of treatment
success and relative pricing. When success is deﬁned as using one
triptan dose to treat one migraine attack in a 24-hour period,
the triptans with the most value to managed care organizations,
in terms of cost per successfully treated patient, are eletriptan 
40mg ($56.39), zolmitriptan 2.5mg ($75.62) and sumatriptan
50mg ($77.59).
